Wang Yilin, Bao Yiping, Liu Jie, Duan Lijun, Cui Yuanshan
Biochip Laboratory, Yantai Yuhuangding Hospital Affiliated to Medical College of Qingdao University, Yantai, China.
Department of Urology, Yantai Yuhuangding Hospital Affiliated to Medical College of Qingdao University, Yantai, China.
Low Urin Tract Symptoms. 2018 Jan;10(1):84-92. doi: 10.1111/luts.12144. Epub 2016 Nov 5.
We carried out a systematic review and meta-analysis to assess tadalafil 5 mg once-daily for the treatment of lower urinary tract symptoms (LUTS) and erectile dysfunction (ED).
A literature review was performed to identify all published randomized double-blind, placebo-controlled trials of tadalafil 5 mg once-daily for the treatment of LUTS and ED. The search included the following databases: MEDLINE, EMBASE, and the Cochrane Controlled Trials Register. The reference lists of the retrieved studies were also investigated.
Thirteen publications involving a total of 3973 patients were used in the analysis, including 13 RCTs that compared tadalafil 5 mg once-daily with placebo. We found that tadalafil 5 mg once-daily was effective in improving LUTS suggestive of BPH and treating ED over 12 weeks in our meta-analysis. Total International Prostate Symptom Score (IPSS) (SMD = - 2.02, 95% CI = - 2.52 to -1.53, P < 0.00001); Benign Prostatic Hyperplasia Impact Index (BPH-II) (SMD = -0.58, 95% CI = -0.84 to -0.33, P < 0.00001); International Index of Erectile Function-erectile function (IIEF) domain (standardized mean difference [SMD] = 5.18, 95% confidence interval [CI] = 4.13-6.23, P < 0.00001) indicated that tadalafil 5 mg once-daily was more effective than the placebo. Safety assessments included discontinuations due to adverse event (odds ratio (OR) = 1.79, 95% CI = 1.12-2.85, P = 0.01) indicated that tadalafil 5 mg once-daily was well tolerated.
This meta-analysis indicates that tadalafil 5 mg once-daily to be an effective treatment for LUTS and ED with a low occurrence of side effects.
我们进行了一项系统评价和荟萃分析，以评估每日一次服用5毫克他达拉非治疗下尿路症状（LUTS）和勃起功能障碍（ED）的效果。
进行文献综述，以确定所有已发表的关于每日一次服用5毫克他达拉非治疗LUTS和ED的随机双盲、安慰剂对照试验。检索包括以下数据库：MEDLINE、EMBASE和Cochrane对照试验注册库。还对检索到的研究的参考文献列表进行了调查。
分析中使用了13篇涉及总共3973名患者的出版物，包括13项将每日一次服用5毫克他达拉非与安慰剂进行比较的随机对照试验（RCT）。我们发现在我们的荟萃分析中，每日一次服用5毫克他达拉非在改善提示良性前列腺增生的LUTS以及在12周内治疗ED方面是有效的。总国际前列腺症状评分（IPSS）（标准化均数差[SMD]=-2.02，95%置信区间[CI]=-2.52至-1.53，P<0.00001）；良性前列腺增生影响指数（BPH-II）（SMD=-0.58，95%CI=-0.84至-0.33，P<0.00001）；国际勃起功能指数-勃起功能（IIEF）领域（标准化均数差[SMD]=5.18，95%置信区间[CI]=4.13 - 6.23，P<0.00001）表明每日一次服用5毫克他达拉非比安慰剂更有效。安全性评估包括因不良事件导致的停药情况（比值比[OR]=1.79，95%CI=1.12至2.85，P=0.01），表明每日一次服用5毫克他达拉非耐受性良好。
这项荟萃分析表明，每日一次服用5毫克他达拉非是治疗LUTS和ED的有效方法，且副作用发生率低。
